Australia Health

Mental health care provider Emyria (ASX:EMD) completed key operational milestones to open its first Sydney clinic in September.

OncoSil Medical (ASX:OSL) has secured $5.6 million in total commitments through a share placement.

Dimerix (ASX:DXB) has entered into an agreement for a $34 million non-dilutive facility to fund its upcoming clinical trial milestones.

Memphasys (ASX:MEM) secured product registration in Turkey for its Felix System, enabling the immediate commencement of commercial sales.

Regis Healthcare (ASX:REG) stated that a 2.55% government funding increase to $303.19 per day falls well below cost inflation.

Prescient Therapeutics (ASX:PTX) reached its pre-specified enrolment threshold of 20 evaluable patients for the Phase 2a trial of its oncology drug PTX-100.

Telix Pharmaceuticals (ASX:TLX) appointed David Gill as chair of the board with immediate effect.

Memphasys (ASX:MEM) signed an exclusive commercialisation agreement with Denmark-based NOVIVITAE to sell and distribute its Felix System.

Racura Oncology (ASX:RAC) activated its first South Korean clinical trial site for its CPACS Phase 1 trial of RC220.

Optiscan (ASX:OIL) has initiated a US-based head and neck cancer imaging study following a research agreement with Mayo Clinic in Rochester.

CSL (ASX:CSL) has entered into agreements with the U.S. to lower domestic drug prices and expand its local manufacturing footprint.

Nanoveu (ASX:NVU) announced that Nanyang Technological University, Singapore, has been granted US Patent No. 12,651,452 B2.